Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...

Biomea Fusion, Inc. has presented promising clinical results for icovamenib, a novel therapy aimed at restoring beta-cell function in patients with type 2 diabetes, at the ATTD 2025 Conference.

In type 1 diabetes, the immune system starts to destroy insulin-producing beta cells in the pancreas. Progressive loss of ...

The old antihypertensive drug verapamil may help reduce insulin requirements and hypoglycemic episodes in adults with type 1 diabetes, new research suggests. Results from the study were published ...

In type 1 diabetes, the immune system starts to destroy insulin-producing beta cells in the pancreas. Progressive loss of these cells destabilizes the body's glucose levels and drives the course of ...

Type 2 diabetes (T2D) is a chronic and widely prevalent condition characterized by a progressive loss of glycemic control driven by both insulin resistance and β-cell dysfunction. The disease has long ...

Can we predict—and prevent—why transplanted beta cells fail? A preclinical study titled “ChemPerturb-seq screen identifies a small molecule cocktail enhancing human beta cell survival after ...

Scientists at City of Hope have uncovered a gene called SMOC1 that plays a surprising role in the development of type 2 diabetes (T2D) by converting pancreatic cells that normally produce insulin into ...

While amyloid β plaques are hallmarks of Alzheimer’s disease (AD), recent research suggests that they aren’t the only players in the neurodegenerative disorder. Genome-wide association studies and RNA ...